Save Product
Product Details
Synonyms
NA, Neuraminidase
Source
Influenza A virus (Darwin/1415/2025) NA (H3N2) Protein, His Tag (NA2-V5244) is expressed from human 293 cells (HEK293). It contains AA Ile 30 - Thr 469 (Accession # EPI_ISL_20237761, GISAID).
Predicted N-terminus: His
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 56.8 kDa. The protein migrates as 65-95 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Purity
>95% as determined by SDS-PAGE.
Formulation
Supplied as 0.2 μm filtered solution in 50 mM Tris, 500 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Shipping
This product is supplied and shipped with dry ice, please inquire the shipping cost.
Storage
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 3 months under sterile conditions.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Influenza A virus (Darwin/1415/2025) NA (H3N2) Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
Bioactivity-ELISA
Immobilized Influenza A virus (Darwin/1415/2025) NA (H3N2) Protein, His Tag (Cat. No. NA2-V5244) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Influenza A virus (A/Darwin/9/2021) NA (H3N2) Antibody, Human IgG1 (8B5) (Cat. No. NEE-MY2392) with a linear range of 0.06-2 ng/mL (QC tested).
Protocol
Immobilized Influenza A virus (Darwin/1415/2025) NA (H3N2) Protein, His Tag (Cat. No. NA2-V5244) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Influenza A virus (A/Darwin/9/2021) NA (H3N2) Antibody, Human IgG1 (2B12) with a linear range of 0.06-2 ng/mL (Routinely tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
